Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.95 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.95 |
| ▸ | PGR | P06401 | 3/20 | 0.95 |
| ▸ | TSHR | P16473 | 2/20 | 0.95 |
| ▸ | AR | P10275 | 2/20 | 0.95 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.95 |
| ▸ | MEN1 | O00255 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.95 |
| ▸ | APEX1 | P27695 | 1/20 | 0.95 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.95 |
| ▸ | IKBKB | O14920 | 1/20 | 0.95 |
| ▸ | CHUK | O15111 | 1/20 | 0.95 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.95 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.95 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.95 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone SCHEMBL7594 | 1.00 | HIF1A (0.95) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL11226476 | 1.00 | HIF1A (0.95) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL28727348 | 0.99 | HIF1A (0.93) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL28258701 | 0.98 | HIF1A (0.92) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL29137991 | 0.98 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL8159683 | 0.97 | HIF1A (0.96) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL29248744 | 0.97 | HIF1A (0.96) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL24556970 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL20816248 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL13479432 | 0.97 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12415 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260108657-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITIS | INSIGNIA PHARMACEUTICALS, LLC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4725558-A2 | IMMUNOABLATIVE THERAPIES | AVM Biotechnology, LLC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4719194-A1 | METHODS FOR INCORPORATING THERAPEUTIC AGENTS INTO ANALYTE SENSORS | Abbott Diabetes Care, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4710918-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR, OPHTHALMIC KIT CONTAINING OPHTHALMIC PHARMACEUTICAL COMPOSITION, AND USE | Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) | 2026-03-18 | — | — | EP | claimed |
| EP-3860612-B1 | IMMUNOABLATIVE THERAPIES | AVM BIOTECHNOLOGY LLC (US) | 2026-03-04 | — | — | EP | claimed |
| US-12551148-B2 | Systems and methods for compensating for agent elution | MEDTRONIC MINIMED, INC. (US) | 2026-02-17 | — | — | US | claimed |
| EP-4683679-A1 | METHOD FOR DIAGNOSING AND TREATING NIS-EXPRESSING CARCINOMAS AND METASTASES | NUSKE, Andreas (DE) | 2026-01-28 | — | — | EP | claimed |
| US-12491289-B2 | Pharmaceutical compositions for treating osteoarthritis | INSIGNIA PHARMACEUTICALS, LLC (US) | 2025-12-09 | — | — | US | claimed |
| EP-4654956-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITIS | Insignia Pharmaceuticals, LLC (US) | 2025-12-03 | — | — | EP | claimed |
| EP-0512050-A4 | DERIVATIVES OF CYCLODEXTRINS EXHIBITING ENHANCED AQUEOUS SOLUBILITY AND THE USE THEREOF | — | 1993-04-21 | — | — | EP | claimed |
| CN-1066395-A | A kind of preparation method of cortical hormone compound preparation for external use | ZHANJIANG MEDICAL COLLEGE (CN) | 1992-11-25 | — | — | CN | claimed |
| EP-0512050-A1 | DERIVATIVES OF CYCLODEXTRINS EXHIBITING ENHANCED AQUEOUS SOLUBILITY AND THE USE THEREOF | THE UNIVERSITY OF KANSAS (US) | 1992-11-11 | — | — | EP | claimed |
| CN-1065996-A | Reduce the method for side reaction of trichosanthes kirilowii protein | SHANGHAI INST ORGANIC CHEM (CN) | 1992-11-11 | — | — | CN | claimed |
| US-5134127-A | Sulfoalkyl Ethers, Solubilizing Agents for Drugs | UNIVERSITY OF KANSAS (US) | 1992-07-28 | — | — | US | claimed |
| WO-1991011172-A1 | DERIVATIVES OF CYCLODEXTRINS EXHIBITING ENHANCED AQUEOUS SOLUBILITY AND THE USE THEREOF | THE UNIVERSITY OF KANSAS (US) | 1991-08-08 | — | — | WO | claimed |
| US-4879274-A | IMPROVED ABSORPTION | KAO CORPORATION (JP) | 1989-11-07 | — | — | US | claimed |
| US-4775667-A | ETHYLENE GLYCOL MONOSALICYLATE, A CORTICOSTEROID AND L-MENTHOL MIXTURE | SHIONOGI & CO., LTD. (JP) | 1988-10-04 | — | — | US | claimed |
| US-4294852-A | WATER, AN ALIPHATIC ALCOHOL AND AN ORGANIC ACID TO ADJUST THE PH OF THE VEHICLE | JOHNSON & JOHNSON (US) | 1981-10-13 | — | — | US | claimed |
| US-3962430-A | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | claimed |